cyrilzakka/clinical-trials huggingface dataset:
Muscle Synergies After Stroke

The aim of this systematic review was to determine the number of muscle synergies and the distribution of muscle weightings in stroke patients during gait.

The aim of this systematic review was to determine the number of muscle synergies and the distribution of muscle weightings in stroke patients during gait. Although literature has suggested that merging of synergies occurs after stroke and that a larger number of is associated with increased motor function if compared with healthy adults. IIt is still unknown if this hypothesis is also relevant when comparing different functional levels within a stroke population and what functional impact of altered synergies on walking behavior is.

Eligibility Criteria:
Inclusion Criteria Stroke:

1. haemorrhagic or ischaemic stroke diagnosis, confirmed on the basis of CT or MRI imaging;
2. no known history of previous stroke;
3. stroke onset within five months; 4 patients are between 18 and 85 years of age;

Exclusion Criteria Stroke:

1. A score of 20 or higher on the Trunk Impairment Scale which indicates normal truncal function;
2. A score lower than two on the Functional Ambulation Categories (FAC) as patients needed to be able to ambulate without physical support to ensure that gait analysis can be executed safely;
3. Not able to sit independently for 30 seconds on a stable surface;
4. They suffer from other neurological and orthopaedic disorders that could influence motor performance and balance;
5. not able to understand instructions.
Association Between Brain Stimulations for the Rehabilitation of Chronic Stroke Patients

Cerebrovascular accident (CVA) is a cerebrovascular disease with high incidence and morbidity in the Brazilian population, and is considered a major cause of disability in adults. Brain damage caused by stroke generates a maladaptive pattern of neural activity and modulation between the cerebral hemispheres, unbalancing in the inter-hemispheric inhibition. This condition affects patient's functional recovery.

The aim of this study is to verify the effectiveness of repetitive transcranial magnetic stimulation Association (rTMS) in the cortex motor contralesional, Transcranial Direct Current Stimulation (tDCS) in the motor cortex ipsilesional and the association between these two types of brain stimulations on the upper limb recovery after stroke.


Eligibility Criteria:
Inclusion Criteria:

* Subcortical stroke diagnosis, which has resulted in hemiparesis for at least 6 months and not more than 5 years (chronic condition);
* Ability to reach 60 degrees in the shoulder flexion
* Ability to completely extend the fingers in the affected upper limb;
* Minimal cognitive ability to understand commands;
* No current use of antiepileptic drugs for seizures.

Exclusion Criteria:

* Painful shoulder, adhesive capsulitis or glenohumeral subluxation;
* Contraindication (presence of metallic implants) or risks for the Transcranial magnetic stimulation, as evaluated by means of a standard questionnaire;
Exercise in Prevention of Metabolic Syndrome

The primary objective of the study is to compare in a real-world setting the efficacy of traditional training (today's guideline, vigorously or moderate exercise) and amount of aerobic interval training (1-AIT) in reduction of risk factors constituting metabolic syndrome.

The secondary objective is to compare the efficacy of traditional moderate training (today's guideline) and amount of aerobic interval training (1-AIT vs. 4-AIT) in improving aerobic capacity, cardiovascular function, skeletal muscle contractile function, skeletal muscle energy metabolism, left ventricle systolic and diastolic function at rest and right ventricular function.

The investigators hypothesized that aerobic interval training would reverse features of the metabolic syndrome more than traditional training.

This study describes a randomized multicenter clinical trial designed to test the hypothesis that a 16-week program, with one year follow up of vigorously exercise defined from today's guidelines (performed as 4-AIT (4x4min aerobe interval training)) yields larger beneficial effects in reducing risk factors constituting the metabolic syndrome than continuously moderate intensity exercise (CME) defined from today's guidelines.

Furthermore, the importance of the amount of aerobic interval training remains unclear and it is unknown how little "one can get away with" and still obtain substantial beneficial cardiovascular effects. Therefore, the investigators will also determine whether one bout of aerobe interval training (AIT) - 1-AIT = 1x4min aerobe interval training, can give beneficial effects compared to 4-AIT and CME.

Evaluation criteria are risk factors constituting metabolic syndrome, aerobic capacity measured as peak oxygen uptake and compliance to intervention. Assessments will be made before and after the 16-week program, and at six month, and 1 and 3 years follow-up. According to estimates based on data from previously studies, 3, 4 a total number of 465 patients randomized 1:1:1 to the three interventions gives 80% power to detect an effect of 4-AIT compared to 1-AIT/CME of 51% recovery versus 37% recovery from metabolic syndrome at the 5% significance level.

Eligibility Criteria:
Inclusion Criteria:

* metabolic syndrome defined according to the IDF-criteria

Exclusion Criteria:

* unstable angina
* recent cardiac infarction (4weeks)
* uncompensated heart failure
* severe valvular illness
* pulmonary disease
* uncontrolled hypertension
* kidney failure
* orthopedic/neurological limitations
* cardiomyopathy
* planned operations during the research period
* reluctant to sign the consent form
* drug or alcohol abuse
* participants in a parallel study
The Prevalence of Psychological and Medical Comorbidities Among Children Suffering From Autistic Spectrum Disorder and the Differences Between Ethnic Groups in Israel

It is known that several psychological and medical comorbidities are frequently found among children suffering from autistic spectrum disorders. Our aim is to investigate which comorbidities are most common among those children and whether there are differences among the different ethnic groups found in Israel.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with autism

Exclusion Criteria:
Mindfulness-based Cognitive Therapy for Chronic Depression

The propose of the study is to investigate the efficacy of Mindfulness-based Cognitive Therapy (MBCT, Segal, Williams, \& Teasdale, 2002) for patients suffering from Chronic Major Depression. The efficacy of MBCT will be compared with the Cognitive Behavioral Analysis System of Psychotherapy (McCullough, 2003), a treatment approach, which has proven it's efficacy yet, and with a treatment-as-usual condition (standard psychiatric outpatient care).

Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a treatment approach specifically developed for the treatment of chronic depression. CBASP aims to change dysfunctional interpersonal patterns. Mindfulness-based Cognitive Therapy (MBCT) has recently been proposed as a further treatment option for chronic depression. MBCT trains patients to step out of negative ruminative states of mind. There are no direct comparisons of the psychological treatment options for chronic depression.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnoses of Major Depression, single episode, chronic or
* Major Depression, recurrent, chronic
* Hamilton Rating Scale for Depression score \> 14
* Beck Depression Inventory II score \> 14

Exclusion Criteria:

* History of Schizophrenia or Schizoaffective Disorder
* Current Substance Dependence or Eating Disorder
* Mental Disorder Due to General Medical Condition
* Borderline Personality Disorder
Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

The purpose of this study is to evaluate the efficacy and safety of MAZ-101 in the treatment of moderate-severe persistent allergic rhinitis.


Eligibility Criteria:
Inclusion Criteria:

* Participants of both sexes, with age greater than or equal to 12 years;
* Clinical diagnosis of moderate-severe persistent for at least 1 year;
* Screening Visit: A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of 2 or 3;
* Randomization Visit: A 12-hour reflective TNSS (AM or PM) ≥ 8 on 3 separate symptoms assessments during the Lead-in Period; an AM or PM 12-hour reflective nasal congestion score of 2 or 3 must have been recorded on 3 separate symptom assessments;
* Present skin sensitization test to at least one aeroallergen.

Exclusion Criteria:

* Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants;
* Other clinical forms of rhinitis;
* Subjects receiving immunotherapy;
* Presence of nasal polyposis;
* Patients with severe arterial hypertension, severe coronary diseases, cardiac arrhythmias, glaucoma, ocular herpes simplex, cataracts, hyperthyroidism;
* Asthma sufferers; respiratory tract infections and lung disease, including chronic obstructive pulmonary disease (COPD);
* Presence of grade II or III septal deviation and/or presence of nasal polyps or other conditions that determine nasal obstruction;
* Concomitant chronic or intermittent use of decongestants and/or antihistamines and/or inhaled, oral, intramuscular, intravenous or potent topical corticosteroids;
* Participants using monoamine oxidase inhibitors (MAOIs);
* Participants with known allergy or hypersensitivity to the components of the drugs used during the clinical trial;
* History of alcohol abuse or illicit drug use;
* Pregnancy or risk of pregnancy and lactating patients;
Prediction of Postoperative Pain by an Electrical Pain Stimulus

The aim of this study is to evaluate a possible correlation between predictive precesarean section pain and development of postcaesarean section pain using the PM.

Patients and Methods 46 healthy pregnant women scheduled for elective cesarean section is included after informed consent. The standard operation procedures included spinal anesthesia, paracetamol 1 g 8 hourly, diclofenac 50 mg 8 hourly and oxycontine 10 mg x 2. Morphine was used for break-through pain.

Before cesarian section the threshold for sensory and pain were measured 3 times, and the average was used for analyses. After cesarian section a blinded midwife assess the pain at rest and during mobilization every 12th hours over 2 days score.

Data was analyzed using AUC and non-parametric test, P \< 0,05.


Eligibility Criteria:
Inclusion Criteria:

* Healthy pregnant women scheduled for elective cesarean section

Exclusion Criteria:

* ASA III -IV
* Chronic pain conditions.
* Pacemaker.
Endovascular vs Surgical Arteriovenous Fistula Outcomes

Arteriovenous fistulas (AVFs) are the preferred type of vascular access for dialysis, but many of them fail to mature. There are two techniques of creating AVFs either the traditional way with surgery( Surgical AVFs) or novel per-cutaneous technique Endo- AVFs.

Investigators will pilot an randomized clinical trial of endo-AVFs and surgical AVFs at University of Alabama at Birmingham to determine the feasibility of patient recruitment, randomization, and retention. This pilot study will set the stage for a full-scale randomized clinical trial in future.

Arteriovenous fistulas (AVFs) are the preferred type of vascular access for dialysis, but many of them fail to mature. Despite concerted efforts to improve surgical AVF outcomes during the past 20 years, many new AVFs fail to mature, even after interventions to salvage them (assisted maturation). Postoperative ultrasounds of immature AVFs frequently demonstrate decreased flow with narrowing at the anastomosis . Surgically created AVFs typically have a 90o angle at the anastomosis, yet computational fluid dynamics suggest that an anastomotic angle \<30o improves the flow hemodynamics. Therefore, there has been great interest in novel AVF technologies to limit vascular injury and improve flow dynamics and maturation rates. The new technology evaluated herein (endovascular AVF (endo-AVF) has the potential to achieve these goals and reduce the cost of vascular access care.

Endo-AVF, a novel per-cutaneous technique of AVF creation, was approved by the FDA in 2018, and has been used in U.S. hemodialysis patients . In contrast to the surgical technique (the current standard), this non-surgical approach (1) minimizes vascular injury at the time of AVF creation and (2) creates a channel between the artery and vein with an angle approaching 0o. These two features provide a scientific rationale for superior maturation compared with that of surgical AVF Investigators will perform a single-center, prospective pilot randomized clinical trial. Investigators will recruit 80 patients who have advanced chronic kidney disease or on hemodialysis with a catheter ,who there pre- operative Ultrasound showed they are eligible to surgical or endo-vascular AVF. Participants will be randomized to one of two groups: an surgical AVF intervention group that will undergo a routine surgical fistula creation, or an endo-vascular AVF intervention group will undergo per-cutaneous fistula creation . Participants will be followed for 2 years.

Eligibility Criteria:
Inclusion Criteria:

* Study will include participants who are 18 years and older who are scheduled to have an AVF
* preoperative ultrasound showed feasibility to have an endo-vascular AVF vs surgical upper arm AVF

Exclusion Criteria:

* Age below 18 years
* participants eligible for low forearm AVF ( radio-cephalic)
Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer

The purpose of this study is to compare the effectiveness four different pain treatments for the injection of radioactive tracer that women with breast cancer receive for sentinel lymph node biopsies.

This study will include women who have been diagnosed with breast cancer and who will be undergoing sentinel lymph node biopsy with a standard injection of radioactive tracer before surgery.

A participant's active participation will take place on two separate occasions. In the first occasion, a participant will complete a brief pain assessment on the day of enrollment. The rest of a participant's active participation will take place on one day (the day of surgery) and last approximately 20 minutes, after which active participation will end.

Primary Objective: To test the effectiveness of four alternative approaches to topical anesthesia on pain associated with radiotracer injection for women diagnosed with breast cancer undergoing sentinel lymph node mapping.

Secondary Objectives:

1. To assess patient satisfaction with pain control modality for radiotracer injection.
2. To identify barriers to implementation of the different pain control interventions.

Eligibility Criteria:
Inclusion Criteria:

* greater than or equal to 18 years of age
* biopsy proven breast cancer
* standard radiotracer injection (intradermal injection in the upper outer quadrant of the involved breast)
* radiotracer injection occurs on the same day as sentinel lymph node surgery

Exclusion Criteria:

* males
* pregnancy
* local anesthetic allergy or active use of the following medications:

  * Abametapir (risk X)
  * Conivaptan (risk X)
  * Fusidic Acid (risk X)
  * Idelalisib (risk X)
  * Mifepristone (risk D)
  * Stiripentol (risk D)
  * Amiodarone (risk C)
  * Dofetilide (risk C)
  * Dronedarone (risk C)
  * Ibutilide (risk C)
  * Sotalol (risk C)
  * Vernakalant (risk C)
* Non-English speaking/reading
* Unable to provide informed consent
* Unable to participate with surveys
* Undergoing radiotracer injection the day prior to surgery or intra-operatively at the time of initial surgical scheduling

  * If patients are initially scheduled for same-day preoperative injection, complete all enrollment procedures (including randomization), and surgery is re-scheduled for a day prior to surgery or for intra-operative injection, they will be excluded if:

    * randomized to a lidocaine patch arm (Arms C or D)
    * re-scheduled for an intra-operative injection • Planned non-standard radiotracer injection site
Impact of Total Nephrectomy on Patients With Kidney Stone

The aim of this study is to investigate the outcomes of total nephrectomy on patients with kidney stone disease.

The aim of this study is to retrospectively investigate the effects of total nephrectomy on renal function, quality of life, early and late complications and development of the stone disease on the remnant unit on patients with kidney stone disease.

Eligibility Criteria:
Inclusion Criteria:

* Total nephrectomy
* Kidney stone disease

Exclusion Criteria:

* \< 18 y.o.
* Cancer
* Kidney transplant
* Solitary kidney
Duration of Immune Response to Influenza Vaccination in Patients With RA

The main objective is to evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents as compared to a group healthy controls who do not have RA. Influenza vaccine titers will be drawn 3 times: at Baseline(prior to vaccination), 4-6 weeks post vaccination, and 5-6 months post vaccination. Influenza vaccination will be done at the baseline visit after the baseline blood draw.

Aims:

* Evaluate the strength and duration of immune response after influenza vaccination in patients with Rheumatoid Arthritis (RA) receiving treatment with biological agents.
* Evaluate for predictors of immune response such as age, gender, disease duration, type of the biological agent(s) used, duration of the treatment, and type of treatment in the past.
* Assess the efficacy of vaccine response in this population by recording proportion of patients who contracted influenza illness despite vaccination. The result of the study may provide more information regarding which situations inadequate immune response by strength or duration would most likely to be expected. This may help lay some groundwork for future studies looking at the use of booster vaccinations in this population

Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria (RA Patients)

* Patients with RA receiving treatment with an Anti-T Cell or Anti-TNF biological agent
* Age 40-75

Inclusion Criteria (Healthy Controls):

* Age 40-75

Exclusion Criteria:

Exclusion criteria (RA Patients)

* Known hypersensitivity/allergy influenza vaccine
* Chronic debilitating conditions (such as end-stage Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), liver disease, Chronic Kidney Disease (CKD) )
* Active malignancy at time of vaccination
* Pregnancy and lactation
* Known HIV
* Active infection at time of vaccination
* Recent acute illness (within 1 month prior to vaccination)

Exclusion Criteria(Healthy Controls):

* Known autoimmune conditions
* Chronic use of immunosuppressant treatments
* Known hypersensitivity/allergy influenza vaccine
* Chronic debilitating conditions (such as end-stage COPD, CHF, liver disease, CKD)
* Active malignancy at time of vaccination
* Pregnancy and lactation
* Known HIV
* Active infection at time of vaccination
* Recent acute illness (within 1 month prior to vaccination)
Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus

Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity and insulin secretion, that above mentioned findings show that dihydromyricetin has an excellent potential effect in the treatment of type 2 diabetes mellitus patients.

A double-blind, randomized clinical trial of three pharmacological groups in 36 patients with a diagnosis of type 2 diabetes mellitus in accordance with the American Diabetes Association (ADA) without treatment.

They will be assigned randomly two groups of 12 patients, each one will receive dihydromyricetin 300 mg or metformin 850 mg, two times per day before having break-fast and before having dinner during 12 weeks.

The Area Under the Curve of glucose and insulin will be calculated, total insulin secretion (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin sensitivity (Matsuda index).

This protocol is already approved by the local ethics committee and written informed consent it's going to be obtained from all volunteers.

Statistical analysis will be presented through measures of central tendency and dispersion, average and deviation standard for quantitative variables; frequencies and percentages for variable qualitative. Qualitative variables will be analyzed by X2, will be used for differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups differences. It will be considered statistical significance p ≤0.05.

Eligibility Criteria:
Inclusion Criteria:

* Patients both sexes
* Age between 30 and 60 years
* Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with one of the following criteria (fasting blood glucose levels \>126 mg/dL; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose \>200 mg/dl; or glycosylated hemoglobin between \>6.5%)
* Informed consent signed

Exclusion Criteria:

* Women with confirmed or suspected pregnancy, or under lactation and/or puerperium
* Previous treatment for glucose
* Fasting glucose ≥250 mg/dL
* Body Mass Index ≥34.9 kg/m2
* Known uncontrolled renal, hepatic, heart or thyroid diseased
* Hypersensibility to ingredients of intervention
* Triglycerides ≥500 mg/dL
* Total cholesterol ≥240 mg/dL
* Blood Pressure ≥140/90 mmHg
Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients

The investigators are studying the correlation between Hba1c and the mean plasma glucose in diabetic hemodialysis patients.We are reviewing if HbA1c is a good clinical tool to assess glycemic control over a 3 months duration in hemodialysis patients

The Hb turnover in hemodialysis population is higher than the general population leading to a general believe that HbA1c tend to underestimate mean plasma glucose.

The investigators are trying to define the correlation between mean plasma glucose and HbA1c in the hemodialysis population and trying to study the factors that could affect this correlation (dose of erythropoetin, ret count..) We are trying to see if HbA1c is a better tool to assess glycemic control over 1 month than glycemic control over 3 month.

This clinicaly will translate in obtaining HbA1c more frequently in hemodialysis patients to assess their glycemic control.

Eligibility Criteria:
Inclusion Criteria:

* Age\>18
* Hemodialysis and diabetic
* Lab data are available for more than 6 months

Exclusion Criteria:

* Lab data not available